Pharmacological ascorbate

Phase 2Small molecule

Pharmacological ascorbate is one of 99 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

GlioblastomaActive, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Preclinical

6 2

Gilotrif

Boehringer Ingelheim

Preclinical

12 3

Pharmacological ascorbate

BBryan Allen

Phase 2

1 4

Ofev

Boehringer Ingelheim

Preclinical

7 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Glioblastoma

NCT04900792

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Completed·JJoseph J. Cullen·Phase 2·NCT02905578·40 enrolled

Glioblastoma1 trial

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Active, not recruiting·BBryan Allen·Phase 1·NCT04900792·17 enrolled

Non-Small Cell Lung Cancer1 trial

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Terminated·WWilliam Zeitler·Phase 1·NCT06083454·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pharmacological ascorbate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pharmacological ascorbate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pharmacological ascorbate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bryan Allen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBryan Allen

Pharmacological ascorbate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pancreatic Cancer1 trial

Glioblastoma1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News